Floatz logo

LENVATINIB

Kidney Neoplasm

Fondazione Policlinico Universitario Agostino Gemelli IRCCSSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Kidney Neoplasm cohort.

Asset / SponsorPhaseRating
Axitinib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Pyruvate
Zhen Wang, MD
Phase 2CCC
Urea
Zhen Wang, MD
Phase 2CCC
Casdatifan
Dana-Farber Cancer Institute
Phase 2CCC
Zimberelimab
Dana-Farber Cancer Institute
Phase 2CCC

View all 9 →

Same molecule, other indications

LENVATINIB is also rated in:

Primary Peritoneal Cavity CancerDormant
BBB
Indicative ·
73 / 100
View asset →
Stage IIB Breast CancerDormant
BBB
Indicative ·
73 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →